Elacestrant

• Description:

  Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo[1][2].

• Product Name Alternative:

  RAD1901

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H312, H332

• Target:

  Estrogen Receptor/ERR

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Elacestrant.html

• Concentration:

  10mM

• Purity:

  99.38

• Solubility:

  DMSO : 160 mg/mL (ultrasonic)

• Smiles:

  OC1=CC=C2C[C@H](C3=CC=C(OC)C=C3N(CC)CC4=CC=C(CCNCC)C=C4)CCC2=C1

• Molecular Formula:

  C30H38N2O2

• Molecular Weight:

  458.63

• Precautions:

  H302, H312, H332

• References & Citations:

  [1]Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26 (9) :948-56.|[2]Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23 (16) :4793-4804.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Biomed Pharmacother. 2024 Nov:180:117523.|bioRxiv. 2023 Nov 2.|bioRxiv. 2024 Jun 2:2024.05.28.596307.|bioRxiv. 2025 Nov 21:2025.11.20.689560.|Genes Dev. 2025 Nov 5.|Harvard University. 2023 Mar. 30487357.|J Cell Mol Med. 2023 Sep;27 (17) :2467-2481.|NPJ Breast Cancer. 2022 Dec 14;8 (1) :130.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2024 Nov 06.|Cancer Discov. 2024 Feb 8;14 (2) :274-289.|Cancer Res. 2024 Dec 16;84 (24) :4283-4297.|J Med Chem. 2020 Oct 8;63 (19) :11085-11099.|Mol Cancer Ther. 2020 Jul;19 (7) :1395-1405.

• CAS Number:

  [722533-56-4]